Triple-negative breast cancer trials in Poland

In Poland 10 Also abroad 425

10 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Bydgoszcz, Cracow, Gdynia, Gliwice, Kielce, Szczecin, Warsaw, Wieliszew
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Cracow, Gdansk, Gliwice, Katowice, Lodz, Lublin, Opole, Poznan, Szczecin, Warsaw, Wroclaw
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Bialystok, Bydgoszcz, Gdynia, Koszalin, Krakow, Poznan, Siedlce, Warsaw, Wieliszew
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Bialystok, Bydgoszcz, Cracow, Kielce, Koszalin, Lodz, Olsztyn, Opole, Slupsk, Walbrzych, Warsaw
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Bialystok, Bydgoszcz, Gdansk, Gdynia, Konin, Krakow, Legnica, Lodz, Lublin, Przemyśl, Warsaw, Wroclaw
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Where
Cracow, Gdansk, Lodz, Warsaw
Age
18 years and over
People
58 worldwide
Run by
AstraZeneca AB
See details and how to join2023-503675-24-00 · EU 2023-503675-24-00
Phase 2/3Not yet taking people in Poland
Prognostic value assessment of PSMA-T4 examination in the group of patients with triple-negative breast cancer (TNBC) qualified to radical therapy
Where
Łódź, Warszawa
Age
18 years and over
People
100
Run by
Narodowe Centrum Badan Jadrowych
See details and how to join2025-525110-29-01 · EU 2025-525110-29-01
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Lodz, Opole, Skorzewo, Warsaw
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00
Phase 3Not yet taking people in Poland
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
Where
DO NOT EDIT
Age
18 years and over
People
765 worldwide
Run by
Women's Cancer Study Group GmbH
See details and how to joinNCT07178730 · EU 2024-516734-35-00
Phase 2Not yet taking people in Poland
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
Where
Gdansk, Gliwice, Opole, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
126
Run by
Medical University of Gdansk
See details and how to joinNCT05067530